Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01045421 · ClinicalTrials.gov registry record · Phase 1
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 273
- Enrollment target
NCT01045421 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 273 participants.
The verdict
NCT01045421, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 273 participants
- Enrollment target
Study Summary
This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
Interventions
- DRUG MLN8237 (Alisertib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01045421
The ClinicalTrials.gov registry entry for NCT01045421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MLN8237 (Alisertib) is the first listed.
NCT01045421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01045421 about?
NCT01045421 is a clinical study titled "Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies". This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
What is the current status of trial NCT01045421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 273 participants. The study started on 2010-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01045421?
The interventions under investigation include: MLN8237 (Alisertib) (DRUG).
Who is sponsoring clinical trial NCT01045421?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.